Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid in Compensated Cirrhosis Due to NASH
NCT03439254Phase 3Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Aug 2017
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
- Countries
- 12
01
Overview
A Phase 3 trial of obeticholic acid in Nonalcoholic steatohepatitis (NASH), sponsored by Intercept Pharmaceuticals. Started Aug 2017; status: completed.
02
Drugs
obeticholic acid
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03439254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439254.